What Is Better for Older Patients With Acute Myeloid Leukemia?
- 20 February 2013
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (6), 820-821
- https://doi.org/10.1200/jco.2012.45.2219
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyHaematologica, 2011
- Azacitidine for the treatment of patients with acute myeloid leukemiaCancer, 2011
- Acute myeloid leukaemia in the elderly: a reviewBritish Journal of Haematology, 2011
- Treatment of Unfit Patients With Acute Myeloid Leukemia: A Still Open Clinical ChallengeClinical Lymphoma Myeloma and Leukemia, 2011
- Hypomethylating agents for the treatment of acute myeloid leukemia in the elderlyCancer, 2011
- Treatment of older patients with acute myeloid leukaemiaThe Lancet, 2010
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer, 2007